From NIH National Cancer Institute Web Sites
From Implementation Database
This database focuses on state and national activities that integrate genomics into public health programs and clinical practice
- Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
[Disease: Cancer; Type: Data; State: Delaware] - BRCA1 and BRCA2: Information for Health Care Professionals
[Disease: Breast Cancer|Ovarian Cancer; Type: Education; State: Illinois] - Hereditary Cancer Center (HCC) at Creighton University
[Disease: Breast Cancer|Lynch syndrome|Ovarian Cancer; Type: Program; State: Nebraska] - Cancer Genetics
[Disease: Lynch syndrome|Ovarian Cancer|Breast Cancer; Type: Education; State: Texas] - BRCA1 & BRCA2
[Disease: Breast Cancer|Ovarian Cancer; Type: Education; State: Illinois]
From Guideline Database
This database contains updated guidelines, policies and recommendations on genomic research and practice, as provided by professional organizations, federal advisory groups, expert panels and policy groups.
- Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015.
Published 2016 (National Comprehensive Cancer Network) - ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes.
Published 2015 (American College of Gastroenterology)
From HuGE Literature Finder Database
This database contains published literature on genetic associations and other human genome epidemiology
- High Prevalence of Mutant KRAS in Circulating Exosome-derived DNA from Early Stage Pancreatic Cancer Patients.
Annals of oncology : official journal of the European Society for Medical Oncology 2017 Jan .
Allenson K, Castillo J, San Lucas F A, Scelo G, Kim D U, Bernard V, Davis G, Kumar T, Katz M, Overman M J, Foretova L, Fabianova E, Holcatova I, Janout V, Meric-Bernstam F, Gascoyne P, Wistuba I, Varadhachary G, Brennan P, Hanash S, Li D, Maitra A, Alvarez - Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer.
Pancreas 2017 Jan .
Hayashi Hideyuki, Kohno Takashi, Ueno Hideki, Hiraoka Nobuyoshi, Kondo Shunsuke, Saito Motonobu, Shimada Yoko, Ichikawa Hitoshi, Kato Mamoru, Shibata Tatsuhiro, Morizane Chigusa, Sakamoto Yasunari, Shimada Kazuaki, Komatsu Yoshito, Sakamoto Naoya, Okusaka Taku - Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer.
Targeted oncology 2016 Dec .
Van Laethem Jean-Luc, Riess Hanno, Jassem Jacek, Haas Michael, Martens Uwe M, Weekes Colin, Peeters Marc, Ross Paul, Bridgewater John, Melichar Bohuslav, Cascinu Stefano, Saramak Piotr, Michl Patrick, Van Brummelen David, Zaniboni Alberto, Schmiegel Wollf, Dueland Svein, Giurescu Marius, Garosi Vittorio L, Roth Katrin, Schulz Anke, Seidel Henrik, Rajagopalan Prabhu, Teufel Michael, Childs Barrett - Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker.
Clinical cancer research : an official journal of the American Association for Cancer Research 2016 Dec .
Pietrasz Daniel, Pécuchet Nicolas, Garlan Fanny, Didelot Audrey, Dubreuil Olivier, Doat Solène, Imbert-Bismut Francoise, Karoui Mehdi, Vaillant Jean-Christophe, Taly Valérie, Laurent-Puig Pierre, Bachet Jean-Baptis - Pancreatic cancer risks associated with prediagnostic plasma levels of leptin and leptin receptor genetic polymorphisms.
Cancer research 2016 Oct .
Babic Ana, Bao Ying, Qian Zhi Rong, Yuan Chen, Giovannucci Edward L, Aschard Hugues, Kraft Peter, Amundadottir Laufey T, Stolzenberg-Solomon Rachael Z, Morales-Oyarvide Vicente, Ng Kimmie, Stampfer Meir J, Ogino Shuji, Buring Julie E, Sesso Howard D, Gaziano John Michael, Rifai Nader, Pollak Michael N, Anderson Matthew L, Cochrane Barbara B, Luo Juhua, Manson JoAnn E, Fuchs Charles S, Wolpin Bri
.png)
No hay comentarios:
Publicar un comentario